Reata and Kyowa Kirin are burying bardoxolone methyl after new phase 3 data laid bare the dwindling—if not non-existent—potential of the kidney disease treatment. The two companies said that while the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback